Nexalin Technology (NXL) shares rose 15% in recent trading Tuesday after the company announced a planned clinical trial for its Gen-3 Halo headset to treat victims of traumatic brain injury.
The trial is in collaboration with the University of California, San Diego, the company said Tuesday in a statement.
The headset will be used in a virtual clinic model, and the trial will evaluate the effectiveness of the device on brain activity and symptom relief in veterans with mild traumatic brain injury, the company said.
Price: 1.71, Change: +0.23, Percent Change: +15.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments